Navigation Links
New Smallpox Vaccine Contract: Five Years in the Making

On December 13, 2002, fifteen months after the 9/11 terrorist attacks, President George W. Bush went to Room 450 of the Dwight D. Eisenhower Executive Office Building next door to the White House and said:

"We know that smallpox still exists in laboratories, and we believe that regimes hostile to the United States may possess this dangerous virus...Our government has no information that a smallpox attack is imminent. Yet it is prudent to prepare for the possibility..."(1)

Smallpox, a highly infectious disease, kills about one-third of the people it infects. It was declared eradicated in 1980, but since 9/11 there has been concern that terrorists might acquire the smallpox virus and purposely release it.

In Denmark, the biopharmaceutical company Bavarian Nordic was ahead of its time in smallpox vaccine development. The company had been working since 1999, long before 9/11, to develop its advanced, third-generation smallpox vaccine called Imvamune(R), an injected vaccine designed to be fast-acting and safe for everyone, regardless of their health condition.

The smallpox vaccine stockpiled by the U.S government, continues to be administered to the military, laboratory workers and some health care professionals but it is not recommended for as much as 25 percent of the population - the young, pregnant women, sufferers from eczema, and persons with immune-compromised systems caused by HIV/AIDS and other conditions - due to side effects and complications caused by the live virus in the vaccine.

Bavarian Nordic's new, patented vaccine, Imvamune(R) is based on the Modified Vaccinia Ankara (MVA) virus. In contrast to stockpiled vaccines, MVA is a live virus but does not replicate in human cells, so the potential for adverse side effects is greatly diminished. This potential - as a new safe and effective smallpox vaccine - attracted significant interest and led to the creation of a government program in 200 2 which then resulted in the award of development contracts for Bavarian Nordic from the National Institute of Allergy and Infectious Disease (NIAID).

When the Department of Health and Human Services (HHS) moved in 2005 to begin a public tender process to purchase an MVA-based smallpox vaccine, Bavarian Nordic was quick to respond. This week, after two years of detailed review, HHS announced that it was awarding a contract to Bavarian Nordic for the manufacture and delivery of Imvamune(R) worth an initial $500 million with contract options that, if exercised, would extend the value to $1.6 billion.

The award highlights a success for the U.S. government's biodefense preparedness programs. This contract is the first time that HHS has utilized all of its existing and newly-acquired payment authorities (Advance Payment, Milestone Advance Payment, and Performance Based Payment) as granted under the original Bioshield legislation (2004), the recently-enacted Pandemic All Hazards Preparedness Act (2006) and the FAR subpart 32.10. Under the contract, Bavarian Nordic will receive $150 million in payments of which $125 million in advance payments will be paid out over the first two years of the contract as milestones are achieved, and $25 million paid during the licensure process.

In addition to its MVA-based smallpox vaccine, Bavarian Nordic is also active in a number of other fields including cancer immunotherapy with a subsidiary in California, BN Immunotherapeutics, Inc., to research and develop MVA-based vaccines against cancer.


'"/>




Related medicine news :

1. Smallpox as Biological Weapons?
2. Is Smallpox Threat Real ?
3. Smallpox Vaccine May Help Fight Cervical Cancer
4. Smallpox Would Spread Rapidly
5. Drug Firm Offers to Donate Smallpox Vaccine
6. Penn Researchers Throw Light on the Structure Of Smallpox Virus Protein
7. Toddler Infected With Rare Side Effect of Smallpox Vaccine
8. Study Finds That Lincoln Suffered from Smallpox During Gettysburg Speech
9. Toddler Infected With Rare Side Effect Of Smallpox Vaccination Recovering
10. Smallpox Alert in Northeast
11. HHS Buys Next Generation Smallpox Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2017)... ... March 27, 2017 , ... Drs. Justin Kolnick, Kara Diamond, ... teaching their patients about the key role this treatment plays in protecting oral health, ... endodontist. To better serve those who need a root canal in White Plains, NY ...
(Date:3/27/2017)... ... March 27, 2017 , ... SyncDog, Inc. , the ... partners LG Business Solutions at ATARC Federal Mobile Computing Summit , March ... provide education and examination into the mobility tools and technology employed by the ...
(Date:3/27/2017)... ... ... The Case Management Society of America (CMSA) will install six new members ... has elected their upcoming President-Elect, Secretary, Treasurer and two Directors to serve on the ... position has also been added to the BOD, per an appointment made by CMSA ...
(Date:3/27/2017)... ... March 27, 2017 , ... Advantexe ... announced the launch of a new research study, The Business Readiness Report. The ... execute that strategy, and the actual success of achieving individual and company goals. ...
(Date:3/27/2017)... ... ... is still in shock after receiving a $2,500 Academic Award from California Casualty . ... , She thinks the coming week is going to be a very joyful for her ... my students.” , The award will allow the 4th grade teacher at Tumwater Hill Elementary ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 27, 2017  Twist Bioscience, a company accelerating science ... that it raised an additional $33 million. To date, ... "It is an exciting time to ... and continue to deliver industry-leading gene volume to our ... Emily M. Leproust, Ph.D., CEO of Twist Bioscience. "We ...
(Date:3/27/2017)... , March 27, 2017  PhaseRx, Inc. (NASDAQ: ... life-threatening inherited liver diseases in children, today reported ... year ended December 31, 2016 and provided an ... "PhaseRx continued to make progress during the fourth ... results from our non-human primate safety study, and with ...
(Date:3/27/2017)... , March 27, 2017 Invivotek, LLC, a ... in vivo pharmacology contract research organization (CRO), ... to its newly expanded preclinical research facility in ... provides a cleaner, renewable energy source to reduce costs ... Completion of the Genesis Solar Farm follows Invivotek,s recent ...
Breaking Medicine Technology: